Managers / Q1 2024 · view latest →
Bain Capital Life Sciences Investors, LLC
CIK 0001703031 · 200 CLARENDON STREET, BOSTON, MA, 02116 · 6175162878
Reported Value
$1.2B
Q1 2024
Positions
26
Filings on Record
30
2019–present window
Filed
May 15, 2024
original filing
Summary
Bain Capital Life Sciences Investors, Llc reported $1.2B in U.S.-listed holdings across 26 positions for Q1 2024.
Its largest position, Newamsterdam Pharma Company, represents 19.9% of the portfolio.
Compared with Q4 2023, the fund opened 2 new positions and exited 3.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q1 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $1.1B | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $1.3B | 19 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $1.5B | 21 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $799M | 23 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $676M | 24 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $850M | 26 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $961M | 24 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $911M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $1.2B | 26 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $1.0B | 27 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $894M | 31 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $971M | 32 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $800,117 | 34 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $895M | 33 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $838M | 33 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $853M | 35 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.0B | 34 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.3B | 34 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.6B | 33 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.5B | 30 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.8B | 31 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.6B | 26 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.1B | 22 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $955M | 15 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $591M | 11 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $671M | 10 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $388M | 7 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $197M | 5 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $250M | 6 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $293M | 6 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 11 additional managers.
- Bain Capital Life Sciences Partners, LP28-18476
- Bain Capital Life Sciences Fund, L.P.28-18478
- BC SW, LP28-20270
- Bain Capital Life Sciences Investors II, LLC28-20816
- Bain Capital Life Sciences Fund II, L.P.28-20814
- BCLS II Investco (GP), LLC28-22976
- BCLS II Investco, LP28-22978
- Bain Capital Life Sciences III General Partner, LLC28-22975
- Bain Capital Life Sciences Fund III, L.P.28-22979
- Bain Capital Life Sciences Opportunities III GP, LLC28-22968
- Bain Capital Life Sciences Opportunities III, LP28-22966
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.